From the Department of Neurobiology, University of Pittsburgh,
Pittsburgh, Pennsylvania 15261 and Department of
Molecular Biomedical Sciences, College of Veterinary Medicine, North
Carolina State University, Raleigh, North Carolina 27606
Received for publication, September 10, 2002, and in revised form, November 8, 2002
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Collagen XVIII is the only currently known
collagen that carries heparan sulfate glycosaminoglycan side chains.
The number and location of the glycosaminoglycan attachment sites in
the core protein were determined by eukaryotic expression of
full-length chick collagen XVIII and site-directed mutagenesis. Three
Ser-Gly consensus sequences carrying glycosaminoglycan side chains were detected in the middle and N-terminal part of the core protein. One of
the Ser-Gly consensus sequences carried a heparan sulfate side chain,
and the remaining two had mixed chondroitin and heparan sulfate side
chains; thus, recombinant collagen XVIII was a hybrid of heparan
sulfate and chondroitin proteoglycan. In contrast, collagen XVIII from
all chick tissues so far assayed have exclusively heparan sulfate side
chains, indicating that the posttranslational modification of proteins
expressed in vitro is not entirely identical to the
processing that occurs in a living embryo. Incubating the various
mutated collagen XVIIIs with retinal basement membranes showed that the
heparan sulfate glycosaminoglycan side chains mediate the binding of
collagen XVIII to basement membranes.
The collagens type XVIII and XV are members of the multiplexins, a
collagen subfamily that is characterized by multiple alternating collagen and non-collagenous domains in the protein sequence (1, 2).
Collagen XVIII came into the public spotlight by the discovery that the
C-terminal peptide of collagen XVIII, named endostatin, has
anti-angiogenic and anti-tumor activities (3, 4). The anti-angiogenic
activity of the peptide led to the idea that collagen XVIII might be
involved in the development of the vascular system. The targeted
deletion of collagen XVIII in mice (5) and a naturally occurring
mutation in human (6), however, showed that its main function is
restricted to the development of the vasculature in the eye but has no
function in blood vessel development in other parts of the body. The
fact that collagen XVIII is, next to collagen IV, the only collagen
that is conserved from Drosophila (7) and
Caenorhabditis elegans (8) to humans suggests an important function of the protein in evolution. The deduced amino acid sequences from collagen XVIII cDNA in mouse and human suggested that collagen XVIII is a proteoglycan (1, 9). It was later revealed by investigating
the naturally occurring protein from chick embryos (10) that collagen
XVIII is a heparan sulfate proteoglycan
(HSPG),1 which is, next to
perlecan and agrin, the third extracellular matrix HSPG currently known
(10, 11). HSPGs are members of a family of cell surface proteins with
polysaccharide side chains characterized by alternating uronic acid and
glucosamine units (12, 13). They occur as either integral membrane (14,
15) or as secreted extracellular matrix proteins (12). The
polysaccharide chains are connected to the core proteins through serine
of the Ser-Gly (SG) consensus sequence whereby the presence of nearby acidic amino acids and the repetition of SGs are factors that promote
attachment of glycosaminoglycan (GAG) side chains and favor synthesis
of heparan sulfate (HS) over chondroitin sulfate (CS) side chains (16,
17). Although the locations of HS chains in syndecan and glypican have
been determined (16, 17), their locations in agrin and collagen XVIII
are unknown. In this study, we expressed the full-length chick collagen
XVIII and determined the number and locations of the GAG chains. Our
results showed that the GAG glycosylation was affected by cell culture
conditions such as the presence or absence of fetal calf serum, and the
preference for attachment of HS and CS was determined by the consensus sequence.
Molecular Cloning of Chick Collagen XVIII DNA by Nested
PCR--
To obtain cDNA sequences covering the entire length of
collagen XVIII, a 2.4-kb chick collagen XVIII 3' cDNA (p10d; Ref.
10) was extended by nested PCR from a random-primed E6 chick amnion library ( Molecular Cloning of Full-length of the Coding Sequence for Chick
Collagen XVIII--
The three PCR clones obtained by nested PCR and
the previously obtained p10d were connected by PCR to obtain a cDNA
for the full-length coding sequence of chick collagen XVIII. The
reaction contained 0.07 pmol each of the DNA segments, a forward primer (5'-TTCGCTAGCTGAGCCCGAGAACCTGAGC-3') that contains an NheI
cutting site in addition to 3 nucleotides to protect the cutting site at 5' end, and a reverse primer (5'-TCTCGAGCTCATTTTTTGGCGGCAGTCATG-3') that contains a XhoI cutting site and 4 protection
nucleotides at the 5' end. The PCR was carried out using Pfu
turbo DNA polymerase. The cycling condition was 94 °C for 1 min and
72 °C for 7 min for 2 cycles; 94 °C for 1 min, 55 °C for 1 min, and 72 °C for 6 min for 2 cycles; and 94 °C for 1 min and
72 °C for 7 min for 30 cycles, following denaturing at 94 °C for
3 min. A 4-kilobase band extracted from the 1% agarose gels was
ligated into pPCR-Script AMP SK(+) vector and transformed into
Ep. coli XL 10-Gold ultracompetent cells as described above.
One of the clones (Full-12) contained the complete chick collagen
XVIII-coding sequence, as confirmed by DNA sequencing.
Site-directed Mutagenesis--
The oligonucleotides used to
generate the mutant constructs are shown in Table
I. Site-directed mutagenesis was carried
out on the Full-12 cDNA clone using the QuikChange site-directed
mutagenesis kit (Stratagene). Briefly, a mutated duplicate of the
original plasmid was produced by PCR using Pfu DNA
polymerase and primers containing the desired mutation. After digestion
of the original plasmid by DpnI, Ep. coli XL
10-Gold ultracompetent cells were transformed with the nicked plasmid,
which contains the desired mutation.
Construction, Expression, and Purification of Recombinant
Collagen XVIII--
Plasmid from Full-12 and the mutated Full-12
clones were digested with NheI and XhoI (New
England Biolabs, Beverly, MA) and de-phosphorylated with alkaline
phosphatase (0.05 units/pmol ends; Roche Molecular Biochemicals). The
digested and de-phosphorylated DNA inserts were isolated from 1%
agarose gels and ligated into an NheI-and
XhoI-digested pCEP-PU expression vector (Ref. 18; kindly
provided by Dr. Mats Paulsson, University of Cologne, Germany). The
plasmid contains a BM40 signal peptide sequence, puromycin-resistant gene, Myc and histidine tags, and a Factor X digestion site at the N
terminus. 293-EBNA cells (Invitrogen) and chick meningeal cells
were transfected with the constructs using LipofectAMINE (Invitrogen).
Stably transfected 293-EBNA cells were cultured in Dulbecco's modified
Eagle's medium, 10% fetal bovine serum (Invitrogen), 1 mM
ascorbic acid, 1% glutamine-penicillin-streptomycin, 350 µg/ml G418,
and 1 µg/ml puromycin (Sigma), and transiently transfected chick
meningeal cells were cultured for 5 days in the culture medium without
G418 and puromycin. Cell culture supernatants (10 ml) were collected
after 24 h of incubation and applied to a Q-Sepharose column (2 ml; Amersham Biosciences) equilibrated with 0.05 M
phosphate buffer (PB) containing 0.15 M NaCl, pH 7.2, to
absorb the collagen XVIII. The columns were washed with PB containing
0.15 M NaCl (10 ml). Non-glycosylated collagen XVIII was
eluted with 0.5 M NaCl in PB (10 ml), and the glycosylated version was eluted with 1.5 M NaCl in PB (10 ml). Fractions
containing collagen XVIII were combined and concentrated to 0.5 ml
using ultrafree-50 centrifugal filter devices (Millipore, Bedford, MA) and dialyzed against Hanks' solution before stored at SDS-PAGE and Western Blotting--
Vitreous body was collected
from E5-E7 chick eyes and centrifuged at 15,000 rpm for 5 min.
Recombinant collagen XVIII was purified by Q-Sepharose chromatography
as described above and dialyzed against calcium- and magnesium-free
Hanks' solution. The samples were subjected to 3.5-15% SDS-PAGE
under reducing conditions. Some of the samples were also run under
non-reducing conditions and without boiling the sample. The proteins
were transferred onto nitrocellulose (Millipore), and the blots were
probed with 6C4, a monoclonal antibody to the NC1 domain of chick
collagen XVIII (10, 19). The proteins were visualized using alkaline phosphatase-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West Grove PA) and 4-nitro blue tetrazolium and
5-bromo-4-chloro-3-indolyl phosphate (Roche Molecular Biochemicals) as
coloring reagents.
Enzyme Treatments--
30 µl of Q-Sepharose-purified
recombinant collagen XVIII and 30 µl of vitreous body supernatant
were used for the digestion. For collagenase treatment, samples were
dialyzed against sodium phosphate buffer (50 mM) containing
0.15 M NaCl (phosphate-buffered saline), pH 7.4, and
incubated with 5 milliunits/µl collagenase (Sigma type VII) and 2%
bovine serum albumin at 37 °C for 1 h. For heparitinase
digestion, the samples were dialyzed against phosphate-buffered saline,
pH 7.0, containing 3 mM CaCl2 and treated with
0.125 milliunits/µl heparitinase (Seikagaku, Rockville, MA) at
37 °C for 2 h. For chondroitinase treatment, the samples were dialyzed against phosphate-buffered saline, pH 8.0, and treated with
0.131 milliunits/µl chondroitinase ABC (Seikagaku) at 37 °C for
2 h. For mixed digestion, the samples were dialyzed against phosphate-buffered saline, pH 7.5, containing 3 mM
CaCl2 and treated with a mixture of heparitinase (0.125 milliunits/µl) and chondroitinase ABC (0.131 milliunits/µl).
Northern Blots--
Northern blotting was performed as described
previously (10). Briefly, total RNA was isolated from E7-E10 chick
brain, embryo, liver, and kidney using TRIzol Reagent (Invitrogen).
Poly(A)+ RNA was purified using PolyATrac mRNA
isolation system IV (Promega, Madison WI), and samples of 2 µg of
poly(A)+ RNA were separated in 1% agarose gels containing 2.2 M formaldehyde, transferred to positively charged nylon
membranes (Immobilon N Millipore), and cross-linked with UV.
Digoxigenin-labeled cRNA hybridization probe was synthesized from the
linearized P12T7P21 collagen XVIII clone template using the
RNA-polymerase labeling kit (Roche Molecular Biochemicals). The
digoxigenin-labeled cRNA hybridized blot was visualized using alkaline
phosphatase-conjugated anti-digoxigenin Fab fragment with
CSPD® ready-to-use chemiluminescent substrates (Roche
Molecular Biochemicals). RNA molecular weight marker II (Roche
Molecular Biochemicals) was used to determine the size of the collagen
XVIII mRNA.
Binding of Collagen XVIII to Retinal Basement Membranes--
A
PAP-pen (EMS, Washington, PA) was used to circle an
~1-cm2 area of a plastic dish coated with nitrocellulose
(20). The hydrophobic ring reduces the volume of the incubation
solutions to less than 100 µl. Retinal basement membranes were
isolated from E6 chick retinae as flat sheets within the encircled
areas of the dishes as described (25). The basement membranes were incubated in 2% Triton X-100 for 1 h to remove cellular debris, and the basement membranes with the surrounding plastic were blocked with 1% bovine serum albumin in 0.2% Triton. The samples were incubated with the supernatant from the transfected EBNA cells for
2 h. After washing in calcium- and magnesium-free Hanks'
solution, the preparations were incubated with a monoclonal antibody to the Myc epitope (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h, washed, and visualized with a Cy-3-labeled goat-anti-mouse secondary
antibody. Binding of collagen XVIII to tissues were done by incubating
sections of paraformaldehyde-fixed heads of the E6 chick embryo with
the cell culture supernatants.
Extension of the cDNA Sequence of Chick Collagen XVIII by
Nested PCR--
A cDNA clone (p10d) for chick collagen XVIII was
previously obtained by conventional screening an E5 chick yolk sac
library with the 6C4 monoclonal antibody. It covers 2.4 kb of the 3'
end of collagen XVIII with 1.24 kb of the 3'-untranslated region (10). To extend the sequence in 5' direction, we sequentially amplified three
collagen XVIII cDNAs from a randomly primed amnion library using a
PCR procedure. Taking the T3 or T7 primer of the library vector as a
forward primer and a specific reverse primer from the 5' end of p10d,
we amplified two DNA bands in the first round of PCR with the T3 primer
and five bands with the T7 primer. In the second round of PCR using the
nested reverse primer, only two DNA bands were obtained with the T7
primer. These bands were slightly smaller in size than the DNA bands
from the first round of PCR, as expected from the close proximity of
the specific reverse primer and the nested reverse primer. One of the
DNA sequences, named INT2T7ANTI22, was homologous to human and mouse
collagen XVIII cDNA. The INT2T7ANTI22 clone contained a 1270-bp
insert and overlapped with p10d by 150 bp. We repeated the procedure using a specific reverse primer and a nested reverse primer designed from INT2T7ANTI22 to obtain P12T7P21 and then from P12T7P21 to obtain
P53T7P64. Both P12T7P21 and P53T7P64 overlapped with their respective
3' predecessors (Fig. 1). The deduced
amino acid sequence of P53T7P64 contained the starting Met codon and a
26-residue signal peptide.
The Complete cDNA Sequence of Chick Collagen XVIII--
A
continuous chick collagen XVIII cDNA sequence was obtained by the
alignment of P53T7P64, P12T7P21, INT2T7ANTI22, and p10d. The sequence
contained 5279 bp with an open reading frame of 4032 bp (Fig. 1) that
corresponded to the short version of human and mouse collagen XVIII
The deduced protein sequence from the cDNA of chick collagen XVIII
In human and mouse tissues, the mRNAs of collagen XVIII Expression and Characterization of Recombinant Chick Collagen
XVIII--
Using P53T7P64, P12T7P21, INT2T7ANTI22, and p10d as
templates and nucleotide sequences from the 5' and 3' end of the
collagen XVIII-coding sequence as primers, we obtained a continuous
cDNA for collagen XVIII by PCR and cloned the cDNA into an
expression vector. The expression construct was stably transfected into
EBNA T293 cells, and the expressed protein was isolated from the cell culture supernatant using Q-Sepharose. The fraction eluted with 0.5 M NaCl contained non-glycosylated collagen XVIII core
protein with an apparent molecular mass of 187 kDa. The GAG-free core protein accounted for less than 5% of total expressed collagen XVIII.
The high salt fraction eluted from the ion exchanger contained GAG-glycosylated collagen XVIII, which appeared as a smear with an
average molecular mass of 350 kDa (Fig.
3, lane 3). In some batches a
small portion of non-glycosylated core protein in the high salt
fraction was also detectable. When non-reduced, unboiled samples were
loaded onto the gels, the recombinant collagen XVIII appeared as a
smear with a molecular mass between 187 and 1000 kDa (Fig. 3,
lane 4). The main part of the smear showed a molecular mass
between 700 and 1000 kDa, identical to the size of non-reduced, unboiled collagen XVIII from vitreous body (Fig. 3, lane 2).
It most likely represents the homotrimer of the collagen XVIII
Collagen XVIII expressed in serum-free medium contained a higher
proportion of core protein, and mobility of the GAG-glycosylated product on SDS-PAGE was higher on average (Fig. 3, lane 5)
than that expressed in the presence of serum (Fig. 3, lane
3). It indicates that serum in the culture medium not only
promoted the degree of glycosylation of collagen XVIII but also
affected the length or negative charge of the GAG side chains.
To prove the collagenous nature of the expressed collagen XVIII, we
digested samples with collagenase and found that the protein was
degraded to several fragments. The molecular mass of the main fragment
was 35 kDa (Fig. 4, lane 4),
identical to the size of the dominant, collagenase-resistant fragment
of vitreous body collagen XVIII (Fig. 4, lane 2). The fact
that the band was recognized by the NC1-specific 6C4 monoclonal
antibody and the size of band was identical to that of collagen XVIII
NC1 confirmed that the fragment is the NC1 domain. To test collagenase
for potential protease contamination, vitreous body samples were
treated with collagenase and probed with an anti-tenascin antibody.
Tenascin, a 220-kDa non-collagenous protein, was not degraded by the
collagenase (Fig. 4, lanes 5 and 6), showing that
the collagenase preparations were free of proteases.
Collagen XVIII expressed in EBNA cells was proteolytically very
sensitive. The degradation fragments on the blots ranged from 51 to 75 kDa (Fig. 3, lane 3, and Fig. 4, lane 3). Based
on their reactivity with the 6C4 monoclonal antibody, they were from
the C-terminal part of the molecule. To prevent degradation, we added a
mixture of commercially available protease inhibitors including 3 µM aprotinin, 50 µM cathepsin B inhibitor
II (Calbiochem), 100 µM E-64, 50 µM
leupeptin, and 100 µM pepstatin into cell culture medium
and the solutions used for Q-Sepharose chromatography. The presence of
inhibitors resulted in slightly different degradation fragments;
however, the average intensity and size of the bands were roughly the
same as those from collagen XVIII expressed without protease inhibitors
present (data not shown). Cathepsin B inhibitor II and E64, which have
been reported to inhibit the release of endostatin at the C terminus
(27), was not effective in preventing degradation of the whole
molecule. In addition, the results showed that the yield of collagen
XVIII increased with longer incubation periods; however, at the same
time, the degradation of collagen XVIII increased even more. As a
compromise, we collected the culture supernatant for purification in
24-h intervals.
GAGs and Their Attachment Sites of the Recombinant Collagen
XVIII--
Similar to the highly glycosylated collagen XVIII from
vitreous, amnion, kidney, and meninges (10), recombinant collagen XVIII
appeared in Western blots as a smear with an apparent molecular mass of
350 kDa (Fig. 5A, lane
1). Treatment with heparitinase caused a slight decrease in size
to 320 kDa and the appearance of a faint band in the size of the core
protein at 187 kDa (Fig. 5A, lane 2). When
treated with chondroitinase ABC, the size of protein shifted to 240 kDa
and the core protein band of 187 kDa became more prominent (Fig.
5A, lane 4). When treated with a mixture of
heparitinase and chondroitinase, the recombinant protein appeared as
two sharp, overlapping bands with molecular mass round 187 kDa, showing
that the recombinant collagen XVIII expressed in 293-EBNA cells is a
hybrid HSPG/chondroitin sulfate proteoglycan (Fig. 5A,
lane 3). An identical GAG composition of HS/CS was also detected with recombinant collagen XVIII expressed in chick meningeal cells (data not shown). To compare GAG composition of recombinant with
that of the natural collagen XVIII, we treated vitreous body collagen
XVIII with the same enzymes. The results confirmed previous experiments
(10, 19), showing that collagen XVIII from all chick tissues so far
tested (vitreous body, kidney, amnion, and meninges) is a heparan
sulfate proteoglycan with no participation of chondroitin sulfate (Fig.
5B).
Recombinant collagen XVIII has eight potential GAG glycosylation sites,
five of which are located in NC-11. Other GAG attachment sites are
located each in COL-10, NC-9, and NC-8. The sequences of potential GAG
attachment sites are listed in Fig. 6.
Sites 2, 3, and 4 appear as a group of three SG residues separated by 3 and 7 residues, respectively. Sites 3, 7, and 8 are conserved between
chick, Xenopus (22), mouse, and human (Fig. 1). To reveal which site is in fact glycosylated, we used site-directed mutagenesis and expressed the mutated protein in EBNA cells. TM278, a triple mutant
in which the serine residues in sites 2, 7, and 8 were substituted by
alanines, appeared as a non-glycosylated protein of 187 kDa (Fig.
7, lane 1), showing that the
glycosylation sites are located at these 3 sites. A double mutant DM78,
in which the serine residues of sites 7 and 8 were substituted with
alanines, showed a smear with an average molecular mass of 235 kDa
(Fig. 7, lane 2). The GAG side chain remaining in DM78
molecules (site 2) shifted in molecular mass only after digestion with
heparitinase (Fig. 8A,
lane 2) or a mixture of heparitinase and chondroitinase ABC
(Fig. 8A, lane 3) but not by chondroitinase alone
(Fig. 8A, lane 4), demonstrating that the
carbohydrate side chain on site 2 is a heparan sulfate GAG. The double
mutant DM28, in which the serine residues of sites 2 and 8 were
substituted by alanines, showed a smear with an average molecular mass
of 280 kDa (Fig. 7, lane 3). The remaining GAG (site 7) in
the DM28 mutant collagen XVIII was completely digested with the mixture
of heparitinase and chondroitinase ABC (Fig. 8B, lane
3) and partially digested with either heparitinase (Fig.
8B, lane 2) or chondroitinase (Fig. 8B, lane 4), suggesting the GAG attached at site
7 is a chondroitin sulfate or heparan sulfate GAG. The abundance of the
core protein after heparitinase or chondroitinase ABC treatment (Fig.
8B, lanes 2 and 4) showed the major
proportion of GAGs attached to site 7 is chondroitin sulfate. The
double mutant DM27, in which the serine residues of sites 2 and 7 were
substituted with alanine, showed a smear with an average molecular mass
of 290 kDa (Fig. 7, lane 4). Similar to site 7, the
carbohydrate at site 8 was sensitive to heparitinase (Fig.
8C, lane 2) and chondroitinase ABC (Fig.
8C, lane 4) and could only be completely digested
with both enzymes (Fig. 8C, lane 3), suggesting that the GAG
attached on site 8 is either chondroitin sulfate or heparan sulfate.
Based on the gel pattern of lanes 2 and 4 in Fig.
8C, the dominant GAG at site 8 is chondroitin sulfate.
The observation that EBNA cells secrete more collagen XVIII core
protein when transfected with doubly or triply mutated as compared with
singly or non-mutated collagen XVIII cDNAs indicates that not all
of the three attachment sites were occupied with GAG side chains in
every collagen XVIII molecule. This would also explain that core
protein bands appeared in all of the mutant samples in Fig. 7. The fact
that the collagen XVIII core protein appeared after heparitinase (Fig.
5A, lane 2) and chondroitinase ABC treatment
(Fig. 5A, lane 4) suggests that some of molecules contain only chondroitin sulfate GAG or only heparan sulfate GAG.
Potential glycosylation sites 2, 3, and 4 are present as three SGs
following each other in short sequence. SG residues of site 2 and 3 are
separated by three residues (DFG; Fig. 6), and the SG residues of site
3 and 4 are separated by seven residues (AGDRHHP; Fig. 6). The results
presented above showed that the serine at site 2 was glycosylated, and
the GAG chain attached to this site was heparan sulfate. To investigate
whether the serine residues in sites 3 and 4 has an effect on
glycosylation of serine in site 2, we substituted the serine residues
in sites 3, 7, and 8 to alanines (TM378) and serine residues in sites
4, 7, and 8 to alanines (TM478). TM478 appeared as a smear with an
average molecular mass of 235 kDa (Fig.
9A, lane 3) and a
banding pattern similar to that of DM78 shown in Fig. 9A,
lane 4. The GAG of TM478 was a heparan sulfate (data not
shown), showing that the mutation of serine at site 4 does not affect
the glycosylation at site 2. Interestingly, TM378 appeared as a smear
with an average molecular mass of 290 kDa (Fig. 9A,
lane 2). The GAG at site 2 was sensitive to both
heparitinase (Fig. 9B, lane 1) and chondroitinase
ABC (Fig. 9B, lane 2) but was entirely digested
only with the mixture of both enzymes (Fig. 9B, lane
3). According to the staining intensities of the core protein
bands after the enzyme digestions (Fig. 9B), the dominant
GAG side chain of TM378 at glycosylation site 2 is chondroitin sulfate.
The result suggests that the assembly of HS or CS at site 2 is affected
by the adjacent serine at site 3.
Binding of Collagen XVIII to Retinal and Tectal Basement
Membranes--
It is well established that collagen XVIII is a
constituent of basement membranes (10, 11). To investigate whether the recombinant collagen XVIII and its mutated versions could bind to
basement membranes, we incubated isolated retinal basement membranes
and sections of chick embryos with collagen XVIII and tested for
binding by using the Myc tag fused to the recombinant protein. As shown
in Fig. 10a, the recombinant
collagen XVIII, which contained mixed CS and HS and mutant DM78 (Fig.
10, c and e), which has exclusively HS, bound to
the retinal basement membrane. The mutant collagen XVIII TM278, which
has no GAG side chains (Fig. 10b), and DM27 (Fig. 10,
d and f) and DM28 (not shown), which have
prominently CS side chains, did not bind to the basement membrane. The
binding data showed that the heparan sulfate side chain on site 2 was
solely responsible for the basement membrane binding.
Cloning of Chick Collagen XVIII by PCR--
For cloning of the
entire collagen XVIII we amplified the missing segments from a
random-primed cDNA library by extending a previously isolated 3'
sequence (p10d) (10). The T3 or T7 promotor sequence, part of the
vector, was used as the forward primer. The only requirement for the
PCR extension was to design a specific and a nested reverse primer from
the known collagen XVIII cDNA. The method turned out to be a very
reliable alternative to the more elaborate 5' rapid amplification of
cDNA 5' ends. Furthermore, it not only was successfully used to
obtain the 5' half of collagen XVIII but also allowed us to extend the
extremely long sequence of laminin Chick Collagen XVIII--
The protein sequence of the chick
collagen XVIII showed a high homology to human and mouse collagen XVIII
with all 10 collagenous and all 11 non-collagenous domains preserved.
The most conserved regions were in the C-terminal NC1 domain, with 90%
homology in the endostatin region. Recombinant chick collagen XVIII was
more sensitive to proteolytic degradation than the endogenous one in vitreous body. The reason, we speculate, is that triple helix formation
is incomplete, as shown by presence of the collagen XVIII monomers in
non-boiled non-reduced samples (Fig. 3). The dominant fragment was from
the C-terminal part of the protein, suggesting that collagen XVIII has
unique features at its C terminus, NC1, part of the molecule making it
very sensitive to degradation. We also have preliminary data showing
that collagen XVIII from vitreous body and the meninges also has its
C-terminal part clipped off, and a naturally existing endostatin-like
peptide was identified in vitreous
body.2 Collagen XVIII in
human and mouse exists in a short and a long version (1, 9, 21),
whereby the long version is highly expressed in liver. Northern blots
with both 3'and 5' probes and 5' rapid amplification of cDNA 5'
ends did not reveal a long version of collagen XVIII in chick tissues.
We speculate that the chick has only the short version of the protein.
GAG Glycosylation of Collagen XVIII--
Eight potential GAG
attachment sites were located in the chick collagen XVIII. Three of
these sites carry GAGs, confirming that collagen XVIII is a
proteoglycan (10). All three attachment sites and their adjacent amino
acids were conserved in human, mouse, and Xenopus collagen
XVIII (22), consistent with the notion that collagen XVIIIs from other
species are also proteoglycans (21). The chick SG consensus sites 1-6
were reduced in human and mouse to 1 single site, suggesting an
evolutionary pressure to maintain at least one SG site at this position
of the protein. The recombinant chick collagen XVIII expressed in
either human 293-EBNA cells or chick meningeal cells turned out to be a
hybrid chondroitin sulfate proteoglycan/HSPG, in contrast to the
endogenous collagen XVIII from chick vitreous body, amnion, kidney, and
meninges, which has only heparan sulfate side chains. Obviously, the
in vitro expression of the protein does not entirely
recapitulate the normal posttranslational modifications that occurs in
the chick embryo, and the unusual posttranslational modification seems irrelevant to the species from which the cells derived.
Previous studies show that the GAGs are connected to the core proteins
via SG consensus sequences. By comparing peptide sequences close to GAG
attachment (16, 17), it was found that the presence of acidic amino
acids before or after the SG sites enhances the chance of a protein
being glycosylated (16). Furthermore, multiple SGs in short sequence
increase the chance of a site becoming connected with a heparan sulfate
side chain (17). Recent studies, however, showed that the clear-cut
identification of an SG consensus sequence as a glycosylation site or
the prediction of the type of glycosylation at a specific site is
impossible. Some peptide domains distant to the SG sites were shown
also to be important in the glycosylation (23, 24). Furthermore, the
fact that endogenous and recombinant chick collagen XVIII is different
in its GAG glycosylation suggests that additional regulatory factors
such as the cell type in which the protein is expressed and cell
culture conditions are also important for glycosylation.
All three GAG attachment sites identified in collagen XVIII fulfill the
requirements postulated for GAG glycosylation, as they have acidic
residues ahead of the SG consensus sequences, and in one case (site 2),
three SGs follow in short distance to each other. Indeed, site 2 is
connected to the HS GAG, as expected, and the mutation of the SG at
site 3 converts the HS into a CS side chain. However, sites 1, 3, and 4 also fulfill the requirements for GAG attachment sites, yet they are
not glycosylated. Additional factors that turned out to be important
for glycosylation were (a) the cell type expressing the
proteins and (b) the growth condition of the cells. Collagen
XVIII from vitreous body, amnion, the meninges, and kidney is a HSPG
and has no CS side chains, in contrast to the recombinant protein in
which 2 of the 3 GAG side chains are substituted for CS. It could mean
that cells from the ciliary body, amnion, kidney, and the meninges, all
of which express collagen XVIII (10, 26), are capable of producing the
fully heparan sulfate-glycosylated protein, whereas the 293-EBNA cells
cannot. This is probably not the case, since chick meningeal cells and 293-EBNA cells produce the same incorrect GAGs in vitro. The
different glycosylation in vivo and in vitro
could mean that growth conditions of cells in a living organism promote
the glycosylation in a way that has not been reproduced in
vitro. It was remarkable that the presence of fetal calf serum in
the culture medium had a strong influence on the properties of the GAG
chains, and it is conceivable that growth factors or signaling
molecules are required to promote the correct glycosylation. The most
reliable predictor for GAG glycosylation in collagen XVIII was the
conservation of the SG consensus sites in different species. All three
sites with GAGs were conserved between human, mouse,
Xenopus, and chick, and an obvious ID for a GAG attachment
site is the conservation of the site throughout different species.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-ZapII; Stratagene, La Jolla, CA). The nucleotide sequence of the T3 or T7 promoter from the library vector was used as the forward primer, and two nucleotide sequences designed from the internal
5' cDNA sequences of p10d were used as the reverse and nested
reverse primer. The first round of PCR contained 4 µl of supernatant
of the boiled and centrifuged library (2 × 1010
plaque-forming unit/ml) and elongase mix as the DNA polymerase (Invitrogen) in a total volume of 40 µl. Bands with the expected molecular weights were extracted from a 1% agarose gel and
re-amplified in the second round of PCR with the T7 or T3 forward
primer and the nested reverse primer. The second round of PCR was
carried out using Pfu turbo DNA polymerase (Stratagene)
following the recommendations provided by the manufacturer. The
re-amplified DNA was extracted from the agarose gel, ligated into
pPCR-Script AMP SK(+) vector, and transformed into Epicurian
coli (Ep. coli)XL 10-Gold ultracompetent cells using
the PCR-Script AMP cloning kit (Stratagene). Plasmids from white
colonies were purified and sequenced in the University of Pittsburgh
Sequencing Facility. The sequences were analyzed using the Sequencer
software (DNA Codes Inc., Ann Arbor, MI) and compared with published
databases using the Blast search algorithm (17). The amino acid
sequence was deduced from the DNA sequence using Sequencher. Three
clones were obtained (P53T7P64, P12T7P21, INT2T7ANTI22) that covered the remaining collagen XVIII cDNA.
Mutagenic oligonucleotides for site-directed mutagenesis of chick
collagen XVIII
80 °C.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (15K):
[in a new window]
Fig. 1.
cDNA clones of chick collagen
1(XVIII) and schematic domain structure of the
deduced polypeptide. The upper part shows overlapping
cDNA clones of P53T7P64, P12T7P21, IN2T7ANTI22, and the previously
reported clone p10d. The positions of starting codon ATG and stop codon
TGA as well as the numbering of nucleotides covered by each cDNA
clone are indicted. The lower part shows the schematic
domain structure of the deduced chick collagen
1(XVIII) in
comparison with the human counterpart. The legends for the structure
are listed at the bottom of the figure.
Collagenous (COL) domains are indicated by wide
rectangles, and non-collagenous (NC) domains are
indicated by thin rectangles. The numbering of the domains
starting from the C-terminal is listed below the diagram.
1. The sequence is deposited in the NCBI gene bank under the access
number AF083440.
1 chain is 1344 amino acids long, with the first 26 amino acid
residues comprising the signal peptide. The chick sequence is slightly
longer than the human (1336) and mouse (1315) short variants (Ref. 21;
Fig. 1). Between chick and human, the overall identity is 61%, and the
homology is 71%, lower than those between human and mouse of 75 and
95%, respectively. Like the human counterpart, chick collagen XVIII
consists of 11 non-collagenous (NC) domains, which are separated by 10 collagenous domains (COL). The N-terminal COL-10 is 71 amino acid
residues long with 2 imperfections in the GXY repeats,
whereas the corresponding COL-10 in human collagen XVIII is 25 residues
(21). Six cysteine residues are present in chick collagen XVIII, two of
which are located in NC11, and four are located in the endostatin
domain of NC1. The presence of cysteine residues was conserved between
chick and human. A potential N-linked glycosylation site
located in COL8 was conserved between chick and human. Another
potential N-linked glycosylation site, present at the
beginning of the NC11, was not conserved. There are eight potential GAG
glycosylation sites in chick collagen XVIII, three of which are in fact
GAG attachment sites (see below).
1 exist
in a short and a long splice variant, with the long version occurring
prominently in liver (1, 9, 21). Attempts to obtain the long version by
rapid amplification of cDNA 5' ends using poly(A)+ RNAs
from chick E6-7 liver and kidney tissues failed (data not shown). The
absence of the long collagen XVIII splice variant in chick was
confirmed by Northern blot analysis: poly(A)+ RNAs from
E6-7 chick liver, kidney, heart, and brain probed with a cRNA probe
synthesized from the 5' clone P12T7P21 (see Fig. 1) showed a single
band of 5.5 kb (Fig. 2). The finding was
consistent with the previous Northern blots probed with the 3' p10d
cRNA probe (see Fig. 1), that also showed a single band at 5.5 kb
(10).
View larger version (50K):
[in a new window]
Fig. 2.
Northern blot analysis of
1(XVIII) collagen mRNA expression in chick
tissues. Each lane contained 2 µg of poly (A)+ RNA
from E7 liver (lane 1), brain (lane 2), heart
(lane 3), and kidney (lane 4). The blot was
probed with the digoxigenin-labeled P12T7P21 cDNA. A single band of
5.5 kb was detected in each sample.
1 chain (10). The lower part of the smear migrated at the same position
as the boiled and reduced collagen XVIII from vitreous body and most
likely represents the collagen XVIII monomer. The presence of monomer
in recombinant collagen XVIII indicates that trimerization is
incomplete.
View larger version (23K):
[in a new window]
Fig. 3.
Western blot of collagen XVIII from chick
vitreous body (lanes 1 and 2) and
recombinant collagen XVIII expressed in EBNA cells (lanes
3-5). The samples in lanes 2 and
4 were not boiled and were run under non-reducing
conditions; the others samples (lane 1, 3, and
5) were reduced and boiled. The blot was probed with the 6C4
anti-chick collagen XVIII monoclonal antibody. The recombinant collagen
XVIII was expressed in Dulbecco's modified Eagle's culture medium
supplemented with 10% fetal bovine serum (lane 3 and
4) or in serum-free medium (50% Dulbecco's modified
Eagle's medium, 50% nutrient mixture F-12, Ham's; lane
5). The collagen XVIII core protein band is indicated by an
arrowhead.
View larger version (17K):
[in a new window]
Fig. 4.
Recombinant collagen XVIII is sensitive to
collagenase. Untreated collagen XVIII, as shown in lane
3, appears as a smear with a molecular mass of about 350 kDa.
After treatment with collagenase, the protein was degraded to a band
with a molecular mass around 35 kDa (lane 4). When vitreous
body samples (lanes 1 and 2 were probed with 6C4;
lanes 5 and 6 were probed with an anti-tenascin
antibody) were treated with collagenase (lane 2 and
6), the band for collagen XVIII shifted to 35 kDa (compare
lane 1 with lane 2), and the band of tenascin did
not shift relative to the band of the untreated sample (compare
lane 5 with lane 6), showing that collagenase was
free of nonspecific proteases.
View larger version (23K):
[in a new window]
Fig. 5.
Western blots comparing the banding pattern
of collagen XVIII from EBNA cells (panel A) and
vitreous body (panel B). The samples were treated
with heparitinase (A and B, lanes 2),
a mixture of heparitinase and chondroitinase (A and
B, lanes 3), or chondroitinase (A and
B, lanes 4). Recombinant collagen XVIII appeared
as a smear with a molecular mass of 350 kDa (A, lane
1). After chondroitinase treatment, the smear shifted to 230 kDa,
and the band of the collagen XVIII core at 187 kDa became visible
(A, lane 4). The protein was slightly reduced in
size after treatment with heparitinase (A, lane
2) and appeared as sharp bands with a molecular mass of 187 kDa
after treatment with a mixture of heparitinase and chondroitinase
(A, lane 3). Collagen XVIII from vitreous body
was a smear of 350 kDa (B, lane 1) that was not
affected by chondroitinase treatment (B, lane 4).
It dropped to a sharp band with a molecular mass of 187 kDa after
treatment with heparitinase (B, lane 2) or a
mixture of heparitinase and chondroitinase (B, lane
3). The collagen XVIII core protein band is indicated by an
arrowhead.
View larger version (19K):
[in a new window]
Fig. 6.
Diagram of collagen XVIII and the locations
of the eight potential GAG attachment sites. The amino acid
sequences of each attachment site are listed. The position of the
serines are indicated by subscripts and numbered from the N-terminal
starting Met.
View larger version (14K):
[in a new window]
Fig. 7.
Western blot of mutant collagen XVIIIs, TM278
(lane 1), DM78 (lane 2), DM28
(lane 3), and DM27 (lane 4). The
blot was probed with the 6C4 antibody. The serines at sites 2, 7 and 8, 7 and 8, 2 and 8, and 2 and 7, were substituted by alanines in TM278,
DM78, DM28, and DM27, respectively. TM278 appeared as sharp bands with
a molecular mass around 187 kDa, corresponding to the collagen XVIII
core protein. The other mutants appeared as diffuse bands, indicating
that long GAG chains are attached to the core protein. The location of
the mutations are indicated by stars in the diagrams, and
the remaining GAG-glycosylated sites are circled. Standard
molecular masses were indicated. The collagen XVIII core protein band
is indicated by an arrowhead.
View larger version (18K):
[in a new window]
Fig. 8.
Western blot showing the type of GAGs
attached to collagen XVIII mutant DM78 (panel A), DM28
(panel B), and DM27 (panel C).
The samples were treated with heparitinase (lane 2), a
mixture of heparitinase and chondroitinase (lane 3), or
chondroitinase (lane 4). Untreated DM78 appeared as a broad
band with a molecular mass of 240 kDa (A, lane
1). The protein was reduced to 187 kDa, the size of the core
protein, after treatment with heparitinase (A, lane
2) or the enzyme mixture (A, lane 3) but was
not affected by treatment with chondroitinase (A, lane
4). Untreated DM28 and DM27 appeared as broad bands with a
molecular mass around 320 kDa (B and C,
lanes 1). The sizes of the proteins were only reduced to a
sharp band of 187 kDa after treatment with both heparitinase and
chondroitinase (B and C, lanes 3).
Treatment with heparitinase shifted the molecular weight only slightly
and led to a minor increase in core protein (B and
C, lanes 2). Chondroitinase digestion led to a
more prominent shift and a major increase of core protein (B
and C, lanes 4). The collagen XVIII core protein
band is indicated by an arrowhead.
View larger version (14K):
[in a new window]
Fig. 9.
Western blots showing that the type of
glycosylation of site 2 is affected by the presence of the adjacent
serine at sites 3 but not the relatively distant serine at site 4. The diagrams show the location of the mutations (stars) and
the glycosylated site 2 in TM378, TM478, and DM78 (circles).
DM78 (A, lane 4) showed a smear of 235 kDa. The
GAG on site 2 in DM78 was shown to be HS (see Figs. 7 and 8). TM478
(A, lane 3), derived from DM78 by substitution of
serine on site 4 with alanine, showed a banding pattern similar to
DM78. TM378 (A, lane 2), derived from DM78 by
substitution of serine on site 3 by alanine, appeared as a smear of 290 kDa. The GAGs on site 2 in TM378 (A, lane 2) can
be partially digested by heparitinase (B, lane 1)
and chondroitinase (B, lane 2) and entirely
digested by a mixture of the two enzymes (B, lane
3; compare with the banding pattern of the triple mutant TM278
with all GAG attachment sites removed, as shown in A,
lane 1). The collagen XVIII core protein band is indicated
by an arrowhead.
View larger version (149K):
[in a new window]
Fig. 10.
Binding of recombinant collagen XVIII to retinal
basement membrane whole mounts (a-c) and the tectal
basement membrane in tissue sections (d). The fully
glycosylated (a) as well as the mutant DM78 collagen XVIII
(c and e) bound to the retinal and tectal
basement membranes. DM78 has only the HS side chain at site 2. The
non-glycosylated (TM278) and DM27 (d and f),
which has little HS but abundant CS at site 8, did not bind.
Bar, 50 µm.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 from the very 5' end in the 3'
direction. Thus, the method was applicable to extend DNA sequences from
any location of the molecule in both directions.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grant NS33981-02.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF083440.
§ To whom correspondence should be addressed: Dept. of Neurobiology, University of Pittsburgh Medical School, E1402 BST, Pittsburgh PA 15261. Tel.: 412-648-9424; Fax: 412-648-1441; E-mail: whalfter@pitt.edu.
Published, JBC Papers in Press, November 13, 2002, DOI 10.1074/jbc.M209276200
2 S. Dong and W. Halfter, unpublished.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: HSPG, heparan sulfate proteoglycan; GAG, glycosaminoglycan; HS, heparan sulfate; CS, chondroitin sulfate; COL, collagenous domain; NC non-collagenous domain, SG, Ser-Gly; PB, phosphate buffer; kb, kilobase(s).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Oh, S. P., Kamagata, Y., Muragaki, Y., Timmons, S., Ooshima, A., and Olsen, B. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4229-4233[Abstract] |
2. | Rehn, M., and Pihlajaniemi, T. (1994) Proc. Natl. Acad. Sci U. S. A. 91, 4232-4238 |
3. | O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997) Cell 88, 277-285[Medline] [Order article via Infotrieve] |
4. |
Sasaki, T.,
Fukai, N.,
Mann, K.,
Goering, W.,
Olsen, B. A.,
and Timpl, R.
(1998)
EMBO J.
17,
4249-4256 |
5. |
Fukai, N.,
Eklund, L.,
Marneros, A. G., Oh, S. P.,
Keene, D. R.,
Tamarkin, L.,
Niemela, M.,
Llves, M., Li, E.,
Pihlajaniemi, M.,
and Olsen, B.
(2002)
EMBO J.
21,
1535-1544 |
6. |
Sertie, A. L.,
Sossi, V.,
Camargo, A. A.,
Zatz, M.,
Brabe, C.,
and Passos-Bueno, M. R.
(2000)
Hum. Mol. Genet.
9,
2051-2058 |
7. |
Hynes, R. O.,
and Zhao, Q.
(2000)
J. Cell Biol.
150,
89-95 |
8. |
Ackley, B. D.,
Crew, J. R.,
Elamaa, H.,
Pihlajaniemi, T.,
Kuo, C. J.,
and Kramer, J. M.
(2001)
J. Cell Biol.
152,
1219-1232 |
9. |
Saarela, J.,
Rehn, M.,
Oikarinen, A.,
Autio-Harmainen, H.,
and Pihlajaniemi, T.
(1998)
Am. J. Pathol.
153,
611-626 |
10. |
Halfter, W.,
Dong, S.,
Schurer, B.,
and Cole, G. J.
(1998)
J. Biol. Chem.
273,
25404-25412 |
11. | Muragaki, Y., Timmons, S., Griffith, C. M., Oh, S. P., Fadel, B., Quertermous, T., and Olsen, B. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8763-8767[Abstract] |
12. | Iozzo, R. (1998) Annu. Rev. Biochem. 67, 609-905[CrossRef][Medline] [Order article via Infotrieve] |
13. |
Esko, J. D.,
and Lindahl, U.
(2001)
J. Clin. Invest.
108,
169-173 |
14. | Rapraeger, A., Jalkanen, M., and Bernfield, M. (1986) J. Cell Biol. 103, 2683-2696[Abstract] |
15. |
Yanagishita, M.,
and Hascall, V. C.
(1992)
J. Biol. Chem.
267,
9451-9454 |
16. |
Zhang, L.,
and Esko, J. D.
(1994)
J. Biol. Chem.
269,
19295-19299 |
17. | Zhang, L., David, G., and Esko, J. D. (1995) J. Biol. Chem. 270, 22127-22135 |
18. | Kohfeldt, E., Maurer, P., Vannahme, C., and Timpl, R. (1997) FEBS Lett. 414, 557-561[CrossRef][Medline] [Order article via Infotrieve] |
19. | Halfter, W., and Schurer, B. (1994) Exp. Cell Res. 214, 285-296[CrossRef][Medline] [Order article via Infotrieve] |
20. | Lagenaur, C., and Lemmon, V. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7753-7757[Abstract] |
21. | Saarela, J., Ylikarppa, R., Rehn, M., Purmonen, S., and Pihlajaniemi, T. (1998) Matrix Biol. 16, 319-328[CrossRef][Medline] [Order article via Infotrieve] |
22. | Elamaa, H., Peterson, J., Pihlajaniemi, T., and Destree, O. (2002) Mech. Dev 114, 109-113[Medline] [Order article via Infotrieve] |
23. |
Dolan, M.,
Horchar, T.,
Rigatti, B.,
and Hassel, J. R.
(1997)
J. Biol. Chem.
272,
4316-4322 |
24. |
Chen, R. L.,
and Lander, A. D.
(2001)
J. Biol. Chem.
276,
7507-7517 |
25. | Halfter, W., Reckhaus, W., and Kroger, S. (1987) J. Neurosci. 7, 3712-3722[Abstract] |
26. | Dong, S., Landfair, J., Balasubramani, M., Bier, M., Cole, G. J., and Halfter, W. (2002) J. Comp. Neurol. 447, 261-273[CrossRef][Medline] [Order article via Infotrieve] |
27. |
Felbor, U.,
Dreier, L.,
Bryant, R. A. L.,
Ploegh, H. L.,
Olsen, B. R.,
and Mothes, W.
(2000)
EMBO J.
19,
1187-1194 |